By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Apitope 



Diepenbeek      Belgium
Phone: n/a Fax: n/a


SEARCH JOBS



Segment
Pharmaceuticals





Company News
Apitope Announces Completion Of Enrolment In Phase IIA Clinical Trial Of ATX-MS-1467 In Relapsing Multiple Sclerosis 8/6/2015 8:50:47 AM
Apitope Release: FDA Grants Orphan Status For ATX-F8-117 For The Treatment Of Haemophilia A Patients In The U.S. 6/9/2015 9:19:15 AM
Abzena To Provide Apitope With Analytical Support For Development Of A Novel Treatment For Factor VIII Inhibitors In Haemophilia A Patients 5/19/2015 10:58:23 AM
Apitope Receives Orphan Designation In The European Union For ATX-F8-117 For The Treatment Of Haemophilia A 11/25/2014 10:24:09 AM
Apitope Treatment Approach Published In Nature Communications 9/4/2014 10:03:42 AM
Apitope Progresses Graves' Disease Treatment 6/19/2014 6:28:29 AM
Apitope Initiates Preclinical Development Of Peptide Therapy, ATX-F8-117, To Treat Factor VIII Intolerance 5/7/2014 9:52:50 AM
Apitope Led Consortium Receives Up To €6M FP7 Funding To Develop Novel Therapeutic Vaccine For Graves' Disease 1/8/2014 9:40:38 AM
Apitope Announces Positive Results From Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 9/3/2013 12:31:58 PM
Apitope Completes Recruitment Into Its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis 11/26/2012 11:26:40 AM
12
//-->